Albuquerque, N.M.-based Agilvax Inc. CEO Joseph Patti told BioWorld that his firm’s antibody-drug conjugate (ADC) method uses “the same linkers, same payloads” as other firms but the “unique factor for us is the target we’re going after” – SLC7A11 (xCT), an amino acid transporter implicated in the metabolic redox activities of metastatic cancer cells.

HONG KONG – In less than a year, China-based Shanghai Miracogen Inc. has extended its partnership with Oss, the Netherlands based Synaffix BV for a second antibody-drug conjugate (ADCs) candidate. The new deal is similar to one signed last year in that it gives Miracogen nonexclusive rights to Synaffix’s Glycoconnect and Hydraspace ADC technologies for use in a second clinical candidate.